This research blend delivers the exact 1:1 ratio used in Novo Nordisk’s Phase 3 CagriSema® program (cagrilintide + semaglutide), now in late-stage trials showing the highest weight-loss efficacy of any incretin therapies to date.
- Cagrilintide – long-acting amylin analog → powerful satiety & gastric emptying delay
- Semaglutide – proven GLP-1/GIP dual agonist → insulin secretion, glucagon suppression, appetite control
Together they produce synergistic effects far exceeding either agent alone, with Phase 3 data reporting up to −22.7% body weight loss at 68 weeks (on-treatment analysis).
Key Scientific
- High-purity Cagrilintide (≥ 98%) + Semaglutide (≥ 99%) by HPLC/MS
- Exact 1:1 clinical ratio (5 mg each = 10 mg total peptide per vial)
- Lyophilized dual-peptide blend for maximum stability
- Full Certificate of Analysis (COA) with HPLC, MS, receptor-binding assays (GLP-1R, GCGR, AMYR), and endotoxin testing
- Manufactured in GMP-aligned, ISO-compliant facilities
- Ideal for triple-pathway synergy, extreme obesity, and T2D research
Research-Referenced Attributes (Clinical & preclinical; not therapeutic claims)
- Phase 3 REDEFINE-1 (n=3,417): CagriSema 2.4/2.4 mg → −22.7%weight loss at 68 weeks vs. −15.6% semaglutide alone
- Phase 3 DREAMS-3 (T2D): HbA1c −2.2% vs. −1.8% semaglutide (p<0.0001)
- Up to 82% liver fat reduction and 58% MASH resolution (Phase 2a)
- Superior triglyceride reduction (−42–60%) and blood pressure lowering
- Once-weekly dosing with excellent tolerability after slow titration
Why Researchers Choose Nationwide Peptides Cagrilintide + Semaglutide 5+5 Blend
- Exact clinical-ratio match to Novo Nordisk’s CagriSema® Phase 3 formulation
- Highest documented weight-loss potency among research incretin blends
- Transparent analytical data (HPLC >98%, dual-receptor binding confirmation)
- Trusted by metabolic disease, obesity, and diabetes research laboratories worldwide
- Competitive pricing with bulk options
